Arkin Moshe 13D and 13G filings for Eiger BioPharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-26 10:01 am Purchase |
2024-08-19 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 149,371 10.090% |
96,300 (+181.46%) |
Filing |
| 2024-07-01 06:47 am Sale |
2024-06-21 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 53,071 3.580% |
-96,300 (-64.47%) |
Filing |
| 2023-12-04 06:01 am Sale |
2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 149,371 10.090% |
-33 (-0.02%) |
Filing |
| 2023-11-24 06:01 am Unchanged |
2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 149,404 10.090% |
0 (Unchanged) |
Filing |
| 2023-04-18 09:59 am Purchase |
2023-04-10 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 149,404 10.150% |
58,971 (+65.21%) |
Filing |
| 2023-02-02 2:25 pm Purchase |
2022-12-31 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 90,433 6.160% |
29,559 (+48.56%) |
Filing |
| 2022-03-08 08:58 am Purchase |
2022-03-01 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
Arkin Moshe | 60,874 5.380% |
60,874 (New Position) |
Filing |